Dick Smith shares smashed in shock guidance downgrade

Published 30-NOV-2015 11:36 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The share price plunge in Dick Smith shares today is what happens when you over promise and under deliver.

At the time of writing, shares in Dick Smith Holdings have been absolutely smashed in early trading, down by over 50% to 32c per share.

The cause? A review of inventory.

It sounds innocuous enough, but after the company’s annual general meeting at the back end of October the company decided, with external consultants, to complete an inventory review.

This is basically checking up on the level of inventory in its warehouses to track sales and potential future sales by applying sales models to the mix, while also making sure it has enough stock to cover the Christmas period.

In its AGM, it lowered FY2016 NPAT guidance by about $5 million to $8 million to a $45-$48 million range.

The downgrade wasn’t exactly cause for joy for shareholders, and was led by an expected softer Christmas trading period.

However, it made this prediction, it seems, with a solid grasp on its expected inventory level.

The fact that it called in outside consultants to get a handle on the situation is admirable, but it really shouldn’t be needed.

While the review hasn’t wrapped up yet, the early results were enough for DSH to abandon its NPAT guidance and announce that a non-cash impairment of $60 million would be required.

“Given the non-cash write down and uncertain trading outlook, the company is unable to re-affirm the profit guidance previously given,” it said in an on-market statement.

Dick Smith Holdings did not give an expected NPAT guidance figure, leaving the market to speculate on the size of the damage.

It would appear in early trading that they have speculated by selling.

In business, the plan is usually to under promise and over deliver, dropping little hints along the way as to the true picture of the company.

The fact a company may make a profit should not be a surprise to shareholders, but the size of the profit should be a nice little upside.

However, it appears that DSH has done pretty much the exact opposite.

A further guidance update will be given in February next year, but there’s no telling at this stage where the bottom is and when bargain-hunters move in, stabilising the crash.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X